Navigation Links
Syngenta Secures EU Approval For Next Generation Fungicide
Date:11/13/2012

BASEL, Switzerland, Nov. 13, 2012 /PRNewswire/ -- Syngenta today announced that it has received European Union (EU) approval for isopyrazam, the first active ingredient from its strong pipeline of next generation fungicides. Approval represents a major step forward in the control of a wide spectrum of damaging fungal diseases, including best-in-class performance against Yellow Rust.

Isopyrazam's advanced "double-binding" technology ensures strong adhesion to fungus and to leaf wax, providing long-lasting and durable disease protection.

Under the EU's provisional approval system, British and Irish cereal farmers have for the past two growing seasons experienced the benefits of isopyrazam, which is marketed as SEGURIS in wheat and BONTIMAin barley. These growers have consistently achieved better disease control, which has helped deliver higher crop yields: SEGURIS treatments increase yield by up to two tonnes per hectare versus current chemistries.

John Atkin, Chief Operating Officer, said: "Breakthrough chemical innovation is an enduring part of our integrated strategy. Isopyrazam sets the highest standards for disease control and yield response and this approval means growers throughout the EU can now benefit from this important addition to our portfolio."

Syngenta intends to register a range of products containing isopyrazam in major EU markets for use on cereals and others crops such as oilseed rape, vegetables and pome fruits.

Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.

Syngenta International AG

Media Office
CH-4002 Basel
Switzerland
Tel: +41 61 323 2323
Fax: +41 61 323 2424

www.syngenta.com

Media contacts:

Paul Barrett
Switzerland +41 61 323 2323

Daniel Braxton
Switzerland +41 61 323 2323

Analyst/Investor contacts:

Jennifer Gough
Switzerland +41 61 323 5059
USA +1 202 737 6521

Lars Oestergaard
Switzerland +41 61 323 6793
USA +1 202 737 6520


'/>"/>
SOURCE Syngenta
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Syngenta and Devgen enter insect control research partnership
2. Syngenta to acquire Pasteuria Bioscience
3. Pasteuria Bioscience to be Acquired by Syngenta
4. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
5. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
6. Roka Bioscience Secures $47.5 Million in Series D Financing
7. Generex Secures Commitments for $3.6M Capital Raise
8. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
9. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
10. Bacterin Secures $25 Million Financing with OrbiMed
11. OncoSec Secures License for Electroporation Intellectual Property from University of South Florida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):